Clinical evolution of beta cell function in youth with diabetes: the SEARCH for Diabetes in Youth study

Diabetologia

Volumn 55, Issue 12, 2012, Pages 3359-3368

  Dabelea, D ^a   Mayer Davis, E J ^b   Andrews, J S ^c   Dolan, L M ^d   Pihoker, C ^e   Hamman, R F ^a   Greenbaum, C ^f   Marcovina, S ^g   Fujimoto, W ^h   Linder, B ⁱ   Imperatore, G ^j   D'Agostino, R ^c  

^a Global Health and Health Disparities   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CINCINNATI   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f BENAROYA RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

^h KUAKINI MEDICAL CENTER   (United States)

ⁱ NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^j NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

more..

Author keywords

Beta cell function; Decline; Determinants; Epidemiology; Type 1 diabetes; Type 2 diabetes; Youth

Indexed keywords

C PEPTIDE; HEMOGLOBIN A1C;

AGE; ANTIBODY DETECTION; ARTICLE; AUTOIMMUNITY; CELL FUNCTION; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DIABETES MELLITUS; ETHNICITY; FEMALE; GENDER; GENETIC HETEROGENEITY; GENETIC SUSCEPTIBILITY; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN SENSITIVITY; LIPID METABOLISM; MALE; MOLECULAR EVOLUTION; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHOOL CHILD;

ADOLESCENT; AGE OF ONSET; AUTOANTIBODIES; BIOLOGICAL MARKERS; BODY MASS INDEX; C-PEPTIDE; CHILD; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; PREDICTIVE VALUE OF TESTS; RISK FACTORS; UNITED STATES;

EID: 84868193197     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-012-2719-6     Document Type: Article

References (48)

1. Steele C, Hagopian WA, Gitelman S et al (2004) Insulin secretion in type 1 diabetes. Diabetes 53:426-433
2. Turner RC, Cull CA, Frighi V, Holman RR (1999) Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281:2005-2012
3. Kahn SE, Montgomery B, Howell W et al (2001) Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 86:5824-5829
4. SteffesMW, Sibley S, Jackson M, ThomasWet al (2003) Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 26:832-836
5. Dahlquist G, Blom L, Persson B, Wallensteen M, Wall S (1988) The epidemiology of lost residual beta-cell function in short term diabetic children. Acta Paediatr Scand 77:852-859
6. Gottsater A, Landin-Olsson M, Lernmark A, Fernlund P, Sundkvist G (1994) Islet cell antibodies are associated with beta-cell failure also in obese adult onset diabetic patients. Acta Diabetologia 31:226-231
7. Wallensteen M, Dahlquist G, Persson B et al (1988) Factors influencing the magnitude, duration, and rate of fall of B cell function in type 1 (insulin-dependent) diabetic children followed for two years from their clinical diagnosis. Diabetologia 31:664-669
8. Bonfati R, Bazzigaluppi E, Calori G et al (1998) Parameters associated with residual insulin secretion during the first year of disease in children and adolescents with type 1 diabetes mellitus. Diabet Med 15:844-850
9. Karjalainen J, Salmela P, Ilonen J, Surcel HM, Knip M (1989) A comparison of childhood and adult type I diabetes mellitus. N Engl J Med 320:881-886
10. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577-1589
11. Sosenko JM, Palmer JP, Rafkin-Mervis L et al (2008) Glucose and C-peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 31:2188-2192
12. Greenbaum CJ, Anderson AM, Dolan LM et al (2009) Preservation of beta-cell function in autoantibody-positive youth with diabetes. Diabetes Care 32:1839-1844
13. Dabelea D, Pihoker C, Talton JW et al (2011) Etiological approach to characterization of diabetes type: The SEARCH for Diabetes in Youth Study. Diabetes Care 34:1628-1633
14. The SEARCH Study Group (2004) SEARCH for Diabetes in Youth: A multicenter study of the prevalence, incidence and classification of diabetes mellitus in youth. Control Clin Trials 25:458-471
15. Bonifacio E, Yu L, Williams AK et al (2010) Harmonization of glutamic acid decarboxylase and islet antigen-2 autoantibody assays for national institute of diabetes and digestive and kidney diseases consortia. J Clin Endocrinol Metab 95:3360-3367
16. Erlich H, Valdes AM, Noble J et al (2008) HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: Analysis of the type 1 diabetes genetics consortium families. Diabetes 57:1084-1092
17. Fernandez JR, Redden DT, Pietrobelli A, Allison DB (2004) Waist circumference percentiles in nationally representative samples of African-American, European-American, and Mexican-American children and adolescents. J Pediatr 145:439-444
18. Dabelea D, D'Agostino RB Jr, Mason CC et al (2011) Development, validation and use of an insulin sensitivity score in youths with diabetes: The SEARCH for Diabetes in Youth study. Diabetologia 54:78-86
19. Ingram DD, Parker JD, Schenker N et al. (2003) United States Census 2000 population with bridged race categories. Vital Health Stat 21-55
20. Kuczmarski RJ, Ogden CL, Guo SS et al (2002) 2000 CDC Growth Charts for the United States: Methods and development. Vital Health Stat 11:1-190
21. Palmer JP, Fleming GA, Greenbaum CJ et al (2004) C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: Report of an ADA workshop, 21-22 October 2001. Diabetes 53:250-264
22. Brown H, Prescott R (2011) Applied mixed models in medicine. Wiley, New York
23. Snorgaard O, Lassen LH, Binder C (1992) Homogeneity in pattern of decline of beta-cell function in IDDM. Prospective study of 204 consecutive cases followed for 7.4 yr. Diabetes Care 15:1009-1013
24. Keymeulen B, Vandemeulebroucke E, Ziegler AG et al (2005) Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352:2598-2608
25. Cook JJ, Hudson I, Harrison LC et al (1989) Double-blind controlled trial of azathioprine in children with newly diagnosed type I diabetes. Diabetes 38:779-783
26. Brown RJ, Sinaii N, Rother KI (2008) Too much glucagon, too little insulin: Time course of pancreatic islet dysfunction in new-onset type 1 diabetes. Diabetes Care 31:1403-1404
27. Herold KC, Gitelman SE, Masharani U et al (2005) A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 54:1763-1769
28. Herold KC, Hagopian W, Auger JA et al (2002) Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346:1692-1698
29. Picardi A, Visalli N, Lauria A et al (2006) Metabolic factors affecting residual beta cell function assessed by C-peptide secretion in patients with newly diagnosed type 1 diabetes. Horm Metab Res 38:668-672
30. Decochez K, Keymeulen B, Somers G et al (2000) Use of an islet cell antibody assay to identify type 1 diabetic patients with rapid decrease in C-peptide levels after clinical onset. Belgian Diabetes Registry. Diabetes Care 23:1072-1078
31. Sabbah E, Savola K, Kulmala P et al (1999) Diabetes-associated autoantibodies in relation to clinical characteristics and natural course in children with newly diagnosed type 1 diabetes. The Childhood Diabetes in Finland Study Group. J Clin Endocrinol Metab 84:1534-1539
32. Kordonouri O, Danne T, Enders I, Weber B (1998) Does the longterm clinical course of type I diabetes mellitus differ in patients with prepubertal and pubertal onset? Results of the Berlin Retinopathy Study. Eur J Pediatr 157:202-207
33. Pozzilli P, Mesturino CA, Crino A, Gross TM, Jeng LM, Visalli N (2001) Is the process of beta-cell destruction in type 1 diabetes at time of diagnosis more extensive in females than in males? Eur J Endocrinol 145:757-761
34. Fernandez CM, Montana E, Camps I et al (1996) Ketoacidosis at diagnosis is predictive of lower residual beta-cell function and poor metabolic control in type 1 diabetes. Diabetes Metab 22:349-355
35. Montana E, Fernandez-Castaner M, Rosel P, Gomez J, Soler J (1991) Age, sex and ICA influence on beta-cell secretion during the first year after the diagnosis of type 1 diabetes mellitus. Diabetes Metab 17:460-468
36. Sosenko JM, Palmer JP, Greenbaum CJ et al (2006) Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 29:643-649
37. Sherry NA, Tsai EB, Herold KC (2005) Natural history of beta-cell function in type 1 diabetes. Diabetes 54(Suppl 2):S32-S39
38. Torn C, Landin-Olsson M, Lernmark A et al (2000) Prognostic factors for the course of beta cell function in autoimmune diabetes. J Clin Endocrinol Metab 85:4619-4623
39. Libman IM, Pietropaolo M, Arslanian SA, LaPorte RE, Becker DJ (2003) Evidence for heterogeneous pathogenesis of insulin-treated diabetes in Black and White children. Diabetes Care 26:2876-2882
40. Tfayli H, Bacha F, Gungor N, Arslanian S (2009) Phenotypic type 2 diabetes in obese youth: Insulin sensitivity and secretion in islet cell antibody-negative versus -positive patients. Diabetes 58:738-744
41. Druet C, Tubiana-Rufi N, Chevenne D, Rigal O, Polak M, Levy- Marchal C (2006) Characterization of insulin secretion and resistance in type 2 diabetes of adolescents. J Clin Endocrinol Metab 91:401-404
42. Elder DA, Prigeon RL, Wadwa RP, Dolan LM, D'Alessio DA (2006) Beta-cell function, insulin sensitivity, and glucose tolerance in obese diabetic and nondiabetic adolescents and young adults. J Clin Endocrinol Metab 91:185-191
43. Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC (1998) UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabetes Med 15:297-303
44. Ekholm E, Gottsater A, Dahlin LB, Sundkvist G (2011) No signs of progressive beta cell damage during 20 years of prospective follow-up of autoantibody-negative diabetes. Acta Diabetol 49:57-62
45. Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR (2001) Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): A randomised, double-blind, phase II trial. Lancet 358:1749-1753
46. Pozzilli P, Pitocco D, Visalli N et al (2000) No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group. Diabetologia 43:1000-1004
47. Chaillous L, Lefevre H, Thivolet C et al (2000) Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: A multicentre randomised controlled trial. Diabete Insuline Orale group. Lancet 356:545-549
48. Greenbaum CJ, Harrison LC (2003) Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetes. Diabetes 52:1059-1065